Overview

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Status:
Recruiting

Trial end date:
2023-08-02

Target enrollment:

Participant gender:

Summary

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.

Phase:

Phase 1

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Atezolizumab
Bevacizumab
Cetuximab
Erlotinib Hydrochloride